SCHEMBL27734720

SCHEMBL27734720

O=CN1CCC(OCc2nc(-c3ccncc3)no2)CC1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 1/20 0.64
RAB9A P51151 6/20 0.50
TSHR P16473 5/20 0.47
RECQL P46063 2/20 0.47
SMN1; SMN2 Q16637 6/20 0.46
NPC1 O15118 5/20 0.46
MAPT P10636 3/20 0.46
LMNA P02545 5/20 0.46
CHRNA7 P36544 1/20 0.45
MEN1 O00255 1/20 0.44
KMT2A Q03164 1/20 0.44
HSD17B10 Q99714 1/20 0.44
S1PR1 P21453 1/20 0.44
NR2F2 P24468 1/20 0.43
STAT3 P40763 1/20 0.43
HTT P42858 1/20 0.43
TP53 P04637 2/20 0.42
HPGD P15428 2/20 0.42
NFKB1 P19838 1/20 0.42
CASP3 P42574 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27747794 0.86 GPR119 (0.66) GPR119RAB9ATSHRRECQLSMN1; SMN2
SCHEMBL1069801 0.83 GPR119 (0.74) GPR119RAB9ATSHRRECQLSMN1; SMN2
SCHEMBL390747 0.82 GPR119 (0.69) GPR119RAB9ATSHRRECQLSMN1; SMN2
SCHEMBL31643339 0.82 GPR119 (0.70) GPR119RAB9ATSHRRECQLSMN1; SMN2
SCHEMBL388894 0.81 GPR119 (0.60) GPR119RAB9ATSHRRECQLSMN1; SMN2
SCHEMBL387143 0.81 GPR119 (0.80) GPR119RAB9ATSHRRECQLSMN1; SMN2
SCHEMBL386607 0.80 GPR119 (0.69) GPR119RAB9ATSHRRECQLSMN1; SMN2
SCHEMBL387294 0.80 GPR119 (0.79) GPR119RAB9ATSHRRECQLSMN1; SMN2
SCHEMBL389587 0.80 GPR119 (0.79) GPR119RAB9ATSHRRECQLSMN1; SMN2
SCHEMBL4528547 0.80 GPR119 (0.58) GPR119RAB9ATSHRRECQLSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101420941-A Use of GPR119 receptor agonists for increasing bone mass and for treating osteoporosis, and related combination therapies ARENA PHARM INC (US) 2009-04-29 CN disclosed
CN-101332303-A Combination therapy for the treatment of diabetes and conditions related thereto and for the treatment of conditions ameliorated by increasing a blood glp-1 level ARENA PHARM INC (US) 2008-12-31 CN disclosed